Sonya Del Tredici and John Keenan

Addiction Medicine Journal Club

Sonya Del Tredici and John Keenan

  • 7. Treating Opioid and Polysubstance Use Disorders

7. Treating Opioid and Polysubstance Use Disorders

Monday 26th September 2022

Drs. Keenan and Del Tredici explore treating opioid use disorder with polysubstance use, comparing buprenorphine and naltrexone, and hospital management guidelines.
33 minutes
Informative
Thought-provoking
Engaging
Educational
Supportive

About this podcast

Addiction Medicine Journal Club
Author:
Sonya Del Tredici and John Keenan
Overview:
Categories:
Innovative Treatments & Recovery Paths
Navigating Alcohol Dependency
Navigating Intimate Relationships
Family Recovery from Addiction
Nutritional Pathways to Recovery
Episodes:
56 (View all)
Rounded Button Dark
Do you want to link to this podcast?
Get the buttons here!

Tackling Opioid and Polysubstance Use: Insights from the Experts

I think that sometimes, though, we use the term polysubstance, and I think often we look at it from like an opioid use disorder lens.
How do you manage opioid use disorder when other substances are in the mix? Dr. John Keenan and Dr. Sonia Del Tredici dive into this challenging topic in this episode of the Addiction Medicine Journal Club. They break down a recent study from JAMA Network Open, comparing the effectiveness of buprenorphine and naltrexone in treating opioid use disorder alongside other substance use.
The hosts also review the Society of Hospital Medicine’s new consensus statement on managing opioid use disorder in hospital settings, offering practical takeaways for healthcare professionals. The episode doesn’t shy away from tough topics, including the risks of liver damage from depot buprenorphine. Drs. Keenan and Del Tredici also explore how the term 'polysubstance' is often used with an opioid-centric view, shedding light on the broader implications for treatment strategies.
This episode is packed with valuable information for anyone involved in addiction medicine, whether you're on the front lines or simply interested in the latest research.